Participated · Series E · Jun 2026

GT Medical Technologies develops GammaTile, an FDA-cleared bioresorbable radiation-emitting implant placed at the time of brain tumor resection to deliver immediate, localized radiation to the surgical bed. The company highlights pivotal ROADS Phase 3 randomized controlled trial results presented at ASCO 2026 showing a 12-month surgical bed recurrence rate of 1.3% with GammaTile versus 15.4% with standard of care and improved survival outcomes. GT recently initiated the BRIDGES randomized controlled trial in newly diagnosed glioblastoma patients and plans to use proceeds from its Series E financing to expand that trial and scale commercial and operational efforts. The company was founded by a team of tumor specialists and announced the Series E from Tempe, Arizona. GT positions GammaTile as eliminating the delay between surgery and postoperative radiation by delivering immediate treatment at the resection site. The firm states the clinical data and new financing support its goal of broader adoption and further clinical development.

Led · Series C · Feb 2026

Neurent Medical is a med-tech company focused on transforming care for chronic inflammatory sinonasal diseases, beginning with chronic rhinitis. Its flagship NEUROMARK System employs proprietary Impedance Controlled Radiofrequency technology to gently disrupt hyperactive posterior nasal nerves, providing durable symptom relief with minimal downtime. The company positions the platform as a differentiated, clinician-friendly alternative that tackles the root cause of rhinitis rather than merely managing symptoms. Headquartered in Galway, Ireland, with U.S. operations in Braintree, Massachusetts, Neurent Medical is expanding commercial availability and building further clinical evidence to support adoption. The newly secured capital will accelerate market penetration, support additional clinical studies across broader populations, and fund development of future indication and product pipeline extensions. The firm has attracted prominent medtech investors and added new board members to guide this next growth phase. No revenue or user metrics were disclosed in the article, but leadership emphasizes scaling sales and broadening evidence as immediate priorities.

Led · Series A · Nov 2025

Founded in 2022 and headquartered in Amsterdam, Avanzanite Bioscience operates a fully integrated pan-European platform for orphan-medicine commercialisation. The company combines market-access expertise, pricing and reimbursement capabilities, and distribution infrastructure to help biotech and pharma partners reach patients in every European country. In its first three years, Avanzanite forged three strategic alliances and actively launched three rare-disease drugs spanning nephrology, ophthalmology and haematology. Management reports that Q3 2025 revenue tripled year-on-year and grew more than 20 percent quarter-on-quarter, underscoring rapid commercial traction. The firm aims to build a portfolio exceeding ten rare-disease partnerships by 2032, thereby establishing a new standard for orphan-drug launches and patient access in Europe. Avanzanite positions itself as the go-to partner for innovators seeking continent-wide reach, ensuring “no patient is left behind” while maximizing the value of orphan therapies.

Led · Series B · Aug 2025

ProVerum Ltd. is a Dublin-based developer of the ProVee® System, an investigational, minimally invasive treatment for BPH. The ProVee System uses a nitinol stent designed to gently re-shape the enlarged prostate and alleviate lower urinary tract symptoms, and is delivered through a low-profile, flexible, steerable delivery system with integrated imaging. The device is investigational and, per the company, is limited by law to investigational use and not available for sale within the United States. ProVerum says proceeds from the financing will be used to prepare for commercialization. The company has emphasized preparing to commercialize its novel treatment for men with BPH as it advances development. Leadership changes accompanying the financing include additions to the board from investor partners.

Participated · Equity · Feb 2025

VitalConnect is a leader in biosensor technology focused on ambulatory cardiac monitoring. Its proprietary biosensor streams eight vital signs and biometric parameters live over a seven-day wear period. The company leverages biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision making and better health and economic outcomes. Its products are designed for use in both remote and in‑patient settings to deliver lower‑cost care and greater convenience for patients and providers. Four years after its commercial launch, VitalConnect reports commercial growth and plans to expand its commercial presence. The company closed $100 million in financing (equity and debt) to accelerate that expansion. VitalConnect develops wearable biosensors and a cloud/mobile platform (the VitalPatch) for real-time remote and in-hospital monitoring. The company leverages biomedical engineering, data analytics, chip design and software to support clinical decision-making and lower healthcare costs. VitalConnect has deployed hundreds of thousands of biosensors globally at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health and John Radcliffe Hospital‑Oxford University. The new funding will support a rapidly growing remote cardiac monitoring business and help advance partnerships with the largest U.S. hospital systems to provide remote patient monitoring in inpatient settings. VitalConnect reports revenue tripled from 2021 to 2022, is on track to nearly double revenue again in 2023, has seen significant EBITDA improvement, and expects to achieve profitability in 2024. VitalConnect is a leader in wearable biosensor technology, offering the VitalPatch for real-time remote and in-hospital monitoring. Founded in 2011 and based in San Jose, Calif., the company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinical decision-making. Its devices have deployed hundreds of thousands of biosensors worldwide and are used in care facilities including Brigham and Women's, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. Products target a broad range of inpatient and outpatient use cases such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect reports strong physician adoption and growth over the past 18 months since launch. The company plans to use new funding to accelerate its cardiac monitoring business and advance remote patient monitoring for heart failure, COPD, sepsis, and other conditions, strengthening commercial access to patients and providers. VitalConnect’s flagship product, the VitalPatch, enables real-time remote and in-hospital patient monitoring. The company combines biomedical engineering, data analytics, chip design, and mobile and cloud software to support clinician decision-making. VitalConnect has deployed more than 200,000 patches worldwide and is used at institutions including Brigham and Women’s, Hackensack Medical Center, Northwell Health, and John Radcliffe Hospital–Oxford University. The company announced a $39 million growth financing to expand its commercial team, scale operations, and develop new products to drive top-line growth. The round was funded by EW Healthcare Partners alongside other new and existing investors, and EW Operating Partner Robert S. White joined VitalConnect’s board. VitalConnect’s products target inpatient and outpatient settings such as hospital monitoring, post-discharge care, cardiac monitoring, and pharmaceutical solutions. VitalConnect develops the VitalPatch wearable biosensor and a software platform for wireless patient monitoring in hospitals and remote settings. The VitalPatch is a small, single-use Class II FDA-approved, band-aid-like device that continuously measures eight vital signs in real time. The company's software platform is already being implemented in select hospitals. Led by founder and CEO Nersi Nazari and launched in 2011, VitalConnect is focused on product development and broader clinical rollout. The company plans to use new funding to continue product development and to roll out the VitalConnect Platform and VitalPatch across hospitals and outpatient settings nationwide. The company has completed multiple funding rounds prior to the current Series C.